"BONU News" BioNeutral Group Signs Agreement to Acquire Steri-7 Combined Product Formulations to Offer an Intergraded Disinfecting Solution for International Distributors, Health Care Providers, Industrial and Institutional Customers, and Consumers
NEWARK, N.J., May 18, 2010 (BUSINESS WIRE) -- BioNeutral Group, Inc. /quotes/comstock/11k!bonu.e (BONU 0.54, 0.00, 0.00%) , a specialty chemical technology-based life science company, announced today the signing of an agreement to acquire all of the shares of Steri-7, a UK manufacturer and supplier of proprietary formulations in the disinfectant and cleaning field with sales in Europe and the Middle East. Steri-7 and BioNeutral technologies offer consistent performance claims for worldwide solutions in the health care and related fields. The parties hope to finish documentation by the end of May and close by the end of July. Terms and conditions are being held confidential.
Steri-7 has sales of approximately one million pounds for this fiscal year and currently offers products for the hospital, nursing home, physician office, police department and equine market in the UK and Europe. Sales have commenced utilizing some of the largest distributors on the continent. Steri-7 and BioNeutral technologies are designed to meet health regulatory requirements in all major markets around the world, offering opportunities and solutions for international distributors to maintain consistent claims and market more effectively.
Jim Fraser, CEO of Steri-7 said: "We are concentrating on Europe and the Middle East, with the best formulations on the market. Our business is growing very fast and it will be exciting to serve large international distributors with an intergraded product line. Bioneutral technology will open up the US and related markets with an overall product line that will create a large successful company."
Nick Sayer, Managing Director Worldwide for Steri-7 said: "7 is approved by the NHS here in the UK and our distributors are doing quite well with our products. Our Steri -- 7 line shows sporicidal results for up to 7 days and we are excited about the prospects of becoming the gold standard in the industry. We just launched our new Equine product line in the US. It works well enough for the Queen's horses and the Aga Kahn as their stables now use Steri-7."
Andy Kielbania, Chief Scientist for Bioneutral, said: "Both of the technology platforms, BioNeutral and Steri-7, can jointly help us create a class of super-products that vastly outperform competing products on the market."
Stephen J. Browand, President and CEO for Bioneutral, said: "This acquisition is designed to produce technologies that can give rise to even better products in the future, while meeting the two regulatory systems--those in the US and the UK--that are adopted by most countries of the world. Large players in the health care and related markets are global, and we believe that this combination of products will be very appealing to a wide range of customers."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.